Isofol Medical AB (ISOFOL) - Total Assets
Based on the latest financial reports, Isofol Medical AB (ISOFOL) holds total assets worth Skr129.40 Million SEK (≈ $13.93 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Isofol Medical AB - Total Assets Trend (2011–2025)
This chart illustrates how Isofol Medical AB's total assets have evolved over time, based on quarterly financial data. Also see market cap of Isofol Medical AB for the company's overall valuation and market capitalisation.
Isofol Medical AB - Asset Composition Analysis
Current Asset Composition (December 2025)
Isofol Medical AB's total assets of Skr129.40 Million consist of 100.0% current assets and 0.0% non-current assets. Review Isofol Medical AB balance sheet liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 32.5% |
| Accounts Receivable | Skr1.42 Million | 1.1% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr0.00 | 0.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Isofol Medical AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Isofol Medical AB (ISOFOL) stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Isofol Medical AB's current assets represent 100.0% of total assets in 2025, an increase from 91.7% in 2011.
- Cash Position: Cash and equivalents constituted 32.5% of total assets in 2025, down from 80.9% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 8.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 1.1% of total assets.
Isofol Medical AB Competitors by Total Assets
Key competitors of Isofol Medical AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH
|
USA | $1.21 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $1.07 Billion |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $543.64 Million |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX
|
USA | $246.58 Million |
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
USA | $235.36 Million |
Isofol Medical AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.19 | 4.96 | 1.21 |
| Quick Ratio | 6.19 | 4.96 | 1.46 |
| Cash Ratio | 0.00 | 4.85 | 0.00 |
| Working Capital | Skr108.48 Million | Skr78.59 Million | Skr17.19 Million |
Isofol Medical AB - Advanced Valuation Insights
This section examines the relationship between Isofol Medical AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.37 |
| Latest Market Cap to Assets Ratio | 0.17 |
| Asset Growth Rate (YoY) | 31.5% |
| Total Assets | Skr129.40 Million |
| Market Capitalization | $22.39 Million USD |
Valuation Analysis
Below Book Valuation: The market values Isofol Medical AB's assets below their book value (0.17x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Isofol Medical AB's assets grew by 31.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Isofol Medical AB (2011–2025)
The table below shows the annual total assets of Isofol Medical AB from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr129.40 Million ≈ $13.93 Million |
+31.48% |
| 2024-12-31 | Skr98.42 Million ≈ $10.59 Million |
-30.00% |
| 2023-12-31 | Skr140.60 Million ≈ $15.13 Million |
-34.14% |
| 2022-12-31 | Skr213.46 Million ≈ $22.97 Million |
-46.82% |
| 2021-12-31 | Skr401.36 Million ≈ $43.19 Million |
+170.95% |
| 2020-12-31 | Skr148.13 Million ≈ $15.94 Million |
+1.13% |
| 2019-12-31 | Skr146.47 Million ≈ $15.76 Million |
-49.24% |
| 2018-12-31 | Skr288.55 Million ≈ $31.05 Million |
-20.13% |
| 2017-12-31 | Skr361.28 Million ≈ $38.88 Million |
+1478.31% |
| 2016-12-31 | Skr22.89 Million ≈ $2.46 Million |
+134.12% |
| 2015-12-31 | Skr9.78 Million ≈ $1.05 Million |
-5.75% |
| 2011-12-31 | Skr10.37 Million ≈ $1.12 Million |
-- |
About Isofol Medical AB
Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden.